Lund, Sweden, 23 February, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at TD Cowen’s 46th Annual Health Care Conference in Boston, at 11:10-11:40 AM EST on Monday 2 March, 2026. Hansa Biopharma CFO Evan Ballantyne, and COO and President U.S. Maria Törnsén, will […]
EMERALD Chief Investigator Prof. Jonathan Fallowfield will present the poster on study design EMERALD is a multicentre Phase I/II study evaluating Resolution’s Regenerative Macrophage Therapy RTX001 in patients with end-stage liver disease taking place in the UK and Spain First patient dosed successfully, and safety cleared at Royal Infirmary of Edinburgh Edinburgh and London, UK, […]
Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress 27 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that CEO, Jeremy Skillington, will be participating in the following leading industry […]
Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for […]
– Oral Presentation of complete data from the three-year MATCH Phase 2 trial – Poster Presentation demonstrating preclinical proof of concept of safety and efficacy of RTX001, an autologous engineered macrophage cell therapy for end stage liver disease Edinburgh and London, UK, 1 October 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company […]
